Rainbow Childrens MedicareQ1 FY24

Rainbow Childrens Medicare Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,270.4P/E: 44.0Market Cap: ₹12.9K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • Revenue for Q1 FY2024 grew by 21% to Rs.287.1 Crores driven by higher delivery numbers, pediatric surgical cases, and addition of 155 beds in 2 units.
  • Outpatient and inpatient volumes increased by 11.6% and 13.9% respectively compared to FY2022.
  • Occupancy in mature hospitals was robust at 47.6%, with new hospitals at 28.1%, expected to improve as they mature.
  • Expansion plan includes adding 270 beds across locations, including new outpatient block with IVF facility in Hyderabad, and 60 beds in central Hyderabad.
  • New hospitals in Bengaluru and Chennai expected to become EBITDA positive soon, with spoke models taking 12-18 months to mature.
  • ARPOB growth is expected around 5-6% annually assuming stable average length of stay.
  • International business targeted to grow to 4% of overall business.
  • Management remains positive on project execution and operational growth for the year.

See what Rainbow Childrens Medicare management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • No explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
  • The company has a strong cash and cash equivalent position of Rs. 474.2 Crores as of June 30, 2023, which includes Rs. 130 Crores from IPO funds.
  • Management expressed confidence in completing all planned capital expenditure (capex) of roughly Rs. 800-900 Crores over the next four years using internal accruals plus the existing cash balance.
  • Annual capex is expected to be between Rs. 200 to 225 Crores in the near term.
  • There are no indications of plans to raise new debt or equity; the company aims to remain cash positive throughout its expansion.
  • The management emphasized reliance on internal cash generation and existing cash reserves without stating any need for fresh fundraising.

See what Rainbow Childrens Medicare management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Rainbow Children’s Medicare Limited plans to build roughly 930 beds over the next 4 years, with an overall capex of approximately Rs. 800 to 900 Crores, including the Gurugram land parcel.
  • As of June 30, 2023, the company holds Rs.474 Crores cash, including Rs.130 Crores IPO funds, supporting the capex plan.
  • Annual capex for FY2024 is expected to be between Rs. 200 to 225 Crores, higher than previous years due to opening 4 hospitals this year and 2 next year.
  • Routine capex is modest, around Rs. 20 to 25 Crores annually; the majority of expenditure is on new projects.
  • The capex spend is spread over the next four years, including the balance of the current year.
  • The company remains confident of being cash positive after completing all announced capex plans through internal accruals and existing cash reserves.

Track Rainbow Childrens Medicare — get its next earnings analysis in your feed

How does Rainbow Childrens Medicare rank vs peers in Healthcare Services?

Pro feature
ThisRainbow Childrens Medicare
Rev 2Mar 3

How does Rainbow Childrens Medicare rank in Healthcare Services?

Compare Rainbow Childrens Medicare against every Healthcare Services company (Q1 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →